Companies
Companies
Ginkgo Bioworks’ Stock Plummets with Massive Layoffs
📢 Ginkgo Bioworks' stock fell 26 after layoffs, but rebounded. ARK selloff also affected the stock. 💰💼💸📈
Novo Nordisk’s Massive Expansion in USA: Manufacturing Innovation for Obesity and Chronic Diseases!
Novo Nordisk's massive expansion in Clayton, NC will boost local economy and create life-saving treatments for chronic diseases. 🏭💊📈
CatSci Expands Chromatography Services with Reach Separations Acquisition
📰 CatSci acquires Reach Separations, expanding chromatography services globally. 🔬 Enhancing CMC capabilities and providing holistic analytical solutions. 💼
Forbion’s Bioeconomy Fund Closes with $75M!
📢 Forbion closes 1st Bioeconomy Fund with $75m! 🌱 Aiming to double to $150m, backed by KfW Capital, Rentenbank, and Novo Holdings. 🚀 sustainability
Revolutionary Oral Drug Delivery: Say Goodbye to Needles!
📢NLC Health Ventures and Verily have partnered to launch Exolvo Biosciences, a game-changing biotech company revolutionizing oral drug delivery. With a flexible capsule size and modular design, Exolvo aims to transform the way biologic drugs are administered. The company is making strides towards FDA approval and collaborating with industry leaders. No more needles! 💉✨
World’s First Chikungunya Vaccine Approved in Canada
📢 Valneva's IXCHIQ® vaccine, the world's first for chikungunya, receives approval in Canada. 💉🌍🩺🌐🌡️
Breaking News: Bota Bio and NHU Join Forces for High-Value Biomanufacturing
📢 Bota Bio and NHU team up in a strategic biomanufacturing partnership to produce top-quality sustainable products. 💼🌱
Novo Nordisk’s $41B Plant Expansion Creates 1000 Jobs and Meets Growing Demand
🏭 Novo Nordisk is building a $4.1B plant in Clayton, NC, creating 1,000 jobs and expanding manufacturing space. 💉💼
Revolutionary Partnership Turbocharges Biopharma Drug Development
🔍 Abzena and Argonaut partner to offer drug development and manufacturing support for biopharma companies. 💊🤝🚀💪👥
Revolutionary Munich Company Doses First Patient with Groundbreaking Cancer Treatment
📢 Tubulis from Munich doses first patient with its ADC candidate TUB-040 targeting NaPi2b antigen in ovarian and lung cancer. 🧪
